La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Electromed Crescita futura

Future criteri di controllo 3/6

Si prevede che Electromed aumenterà gli utili e i ricavi rispettivamente del 19.7% e 11.1% all'anno, mentre si prevede che l'EPS crescerà del 15.8% all'anno.

Informazioni chiave

19.7%

Tasso di crescita degli utili

15.8%

Tasso di crescita dell'EPS

Medical Equipment crescita degli utili	17.4%
Tasso di crescita dei ricavi	11.1%
Rendimento futuro del capitale proprio	n/a
Copertura analitica	Low
Ultimo aggiornamento	08 May 2024

Aggiornamenti recenti sulla crescita futura

Recent updates

What Percentage Of Electromed, Inc. (NYSEMKT:ELMD) Shares Do Insiders Own?

Mar 07

Is Electromed, Inc.'s (NYSEMKT:ELMD) Latest Stock Performance A Reflection Of Its Financial Health?

Feb 17

Electromed, Inc.'s (NYSEMKT:ELMD) Intrinsic Value Is Potentially 90% Above Its Share Price

Dec 16

Announcing: Electromed (NYSEMKT:ELMD) Stock Soared An Exciting 405% In The Last Five Years

Dec 04

How Is Electromed's (NYSEMKT:ELMD) CEO Paid Relative To Peers?

Nov 22

Previsioni di crescita degli utili e dei ricavi

NYSEAM:ELMD - Stime future degli analisti e dati finanziari passati (USD Millions )
Data	Ricavi	Guadagni	Flusso di cassa libero	Liquidità dell'operazione	Avg. Numero di analisti
6/30/2025	61	6	N/A	N/A	1
6/30/2024	55	5	N/A	N/A	1
3/31/2024	53	4	5	6	N/A
12/31/2023	52	4	4	5	N/A
9/30/2023	50	3	1	3	N/A
6/30/2023	48	3	0	1	N/A
3/31/2023	46	3	-2	0	N/A
12/31/2022	44	2	-3	-1	N/A
9/30/2022	42	2	-3	-2	N/A
6/30/2022	42	2	-2	-1	N/A
3/31/2022	40	2	0	1	N/A
12/31/2021	39	2	1	1	N/A
9/30/2021	38	2	1	2	N/A
6/30/2021	36	2	3	3	N/A
3/31/2021	33	3	3	4	N/A
12/31/2020	33	4	3	4	N/A
9/30/2020	32	4	4	4	N/A
6/30/2020	32	4	3	4	N/A
3/31/2020	34	4	2	4	N/A
12/31/2019	33	4	2	4	N/A
9/30/2019	32	3	1	3	N/A
6/30/2019	31	2	1	3	N/A
3/31/2019	31	2	1	2	N/A
12/31/2018	30	2	1	2	N/A
9/30/2018	29	2	2	2	N/A
6/30/2018	28	2	2	2	N/A
3/31/2018	28	2	2	2	N/A
12/31/2017	27	2	N/A	3	N/A
9/30/2017	27	2	N/A	3	N/A
6/30/2017	26	2	N/A	1	N/A
3/31/2017	24	2	N/A	1	N/A
12/31/2016	24	1	N/A	1	N/A
9/30/2016	23	2	N/A	1	N/A
6/30/2016	23	2	N/A	2	N/A
3/31/2016	22	2	N/A	3	N/A
12/31/2015	21	2	N/A	3	N/A
9/30/2015	20	1	N/A	2	N/A
6/30/2015	19	1	N/A	3	N/A
3/31/2015	19	1	N/A	3	N/A
12/31/2014	18	0	N/A	2	N/A
9/30/2014	17	-1	N/A	2	N/A
6/30/2014	15	-1	N/A	2	N/A
3/31/2014	15	-2	N/A	2	N/A
12/31/2013	14	-1	N/A	2	N/A
9/30/2013	14	-2	N/A	3	N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: La crescita prevista degli utili di ELMD ( 19.7% all'anno) è superiore al tasso di risparmio ( 2.5% ).

Guadagni vs Mercato: Si prevede che gli utili di ELMD ( 19.7% all'anno) cresceranno più rapidamente del mercato US ( 15.1% all'anno).

Guadagni ad alta crescita: Si prevede che gli utili di ELMD cresceranno, ma non in modo significativo.

Ricavi vs Mercato: Si prevede che il fatturato di ELMD ( 11.1% all'anno) crescerà più rapidamente del mercato US ( 8.8% all'anno).

Ricavi ad alta crescita: Si prevede che il fatturato di ELMD ( 11.1% all'anno) crescerà più lentamente di 20% all'anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Dati insufficienti per determinare se il Return on Equity di ELMD è previsto essere elevato tra 3 anni

Electromed Crescita futura

Future criteri di controllo 3/6

Informazioni chiave

Aggiornamenti recenti sulla crescita futura

Consensus EPS estimates fall by 25%, revenue upgraded

Price target increased to US$16.75

Consensus forecasts updated

Electromed, Inc. Provides Preliminary Unaudited Earnings Guidance for the Fourth Quarter Ended June 30, 2021

Consensus forecasts updated

Price target increased to US$18.00

Recent updates

Electromed, Inc. to Report Q4, 2024 Results on Aug 27, 2024

Investor sentiment deteriorates as stock falls 17%

Third quarter 2024 earnings: EPS exceeds analyst expectations

New minor risk - Share price stability

Electromed, Inc. to Report Q3, 2024 Results on May 07, 2024

Investor sentiment improves as stock rises 16%

President recently bought US$137k worth of stock

Investor sentiment improves as stock rises 48%

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Electromed, Inc. to Report Q2, 2024 Results on Feb 13, 2024

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Electromed, Inc. Announces Launch of SmartVest Clearway Airway Clearance System

Electromed, Inc. to Report Q1, 2024 Results on Nov 07, 2023

Electromed, Inc., Annual General Meeting, Nov 10, 2023

Consensus EPS estimates fall by 25%, revenue upgraded

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Electromed, Inc. to Report Q4, 2023 Results on Aug 22, 2023

Electromed, Inc. Announces Appointment of Jim Cunniff as Its New President and Board of Director, Effective July 1, 2023

Third quarter 2023 earnings: EPS exceeds analyst expectations

CEO, President & Director exercised options and sold US$245k worth of stock

Investor sentiment improves as stock rises 15%

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Electromed, Inc. Announces Retirement of Kathleen Skarvan as Chief Executive Officer, Effective on or Around July 1, 2023

Electromed, Inc. to Report Q2, 2023 Results on Feb 14, 2023

Electromed, Inc. Announces U.S. Food and Drug Administration 510(K) Clearance of Fifth Generation Hfcwo Airway Clearance Generator

Price target increased to US$16.75

First quarter 2023 earnings: EPS misses analyst expectations

Electromed, Inc. to Report Q1, 2023 Results on Nov 08, 2022

Electromed, Inc. Appoints Brad Nagel as Chief Financial Officer, Effective November 14, 2022

Electromed, Inc., Annual General Meeting, Nov 11, 2022

CEO, President & Director exercised options and sold US$59k worth of stock

Investor sentiment improved over the past week

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Electromed, Inc. to Report Q4, 2022 Results on Aug 23, 2022

High number of new directors

Electromed, Inc. Announces Election of Andrew Summers as Additional Independent Director

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Electromed, Inc. Announces Executive Changes

Electromed, Inc. to Report Q3, 2022 Results on May 10, 2022

Consensus forecasts updated

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

First quarter 2022 earnings released: EPS US$0.051 (vs US$0.063 in 1Q 2021)

Investor sentiment improved over the past week

Full year 2021 earnings released: EPS US$0.28 (vs US$0.49 in FY 2020)

Electromed, Inc. Provides Preliminary Unaudited Earnings Guidance for the Fourth Quarter Ended June 30, 2021

Summers Value Fund Engages in Discussion with Electromed Shareholders

Electromed, Inc.(NYSEAM:ELMD) dropped from Russell 3000 Growth Index

Electromed, Inc. (NYSEAM:ELMD) announces an Equity Buyback for $3 million worth of its shares.

Consensus forecasts updated

Third quarter 2021 earnings released: EPS US$0.026 (vs US$0.078 in 3Q 2020)

Price target increased to US$18.00

What Percentage Of Electromed, Inc. (NYSEMKT:ELMD) Shares Do Insiders Own?

Is Electromed, Inc.'s (NYSEMKT:ELMD) Latest Stock Performance A Reflection Of Its Financial Health?

Analysts increase EPS estimates to US$0.34

Revenue and earnings beat expectations

Second quarter 2021 earnings released: EPS US$0.14 (vs US$0.14 in 2Q 2020)

New 90-day high: US$10.76

Should You Be Impressed By Electromed's (NYSEMKT:ELMD) Returns on Capital?

Electromed, Inc. to Report Q2, 2021 Results on Feb 09, 2021

Did Electromed, Inc. (NYSEMKT:ELMD) Insiders Sell Shares?

Electromed (NYSEMKT:ELMD) Is Growing Earnings But Are They A Good Guide?

New 90-day high: US$10.40

Here's Why I Think Electromed (NYSEMKT:ELMD) Might Deserve Your Attention Today

Electromed, Inc.'s (NYSEMKT:ELMD) Intrinsic Value Is Potentially 90% Above Its Share Price

Announcing: Electromed (NYSEMKT:ELMD) Stock Soared An Exciting 405% In The Last Five Years

How Is Electromed's (NYSEMKT:ELMD) CEO Paid Relative To Peers?

Electromed, Inc. Names Andrea M. Walsh to Serve as an Additional Director

First quarter 2021 earnings released: EPS US$0.063

Revenue and earnings beat expectations